Heightened EGFR/K-RAS/MAPK activation has multiple deleterious effects on the tumor/tumor microenvironment (TME), which is associated with decreased tumor-infiltrating lymphocytes (TIL) detection in TNBC and is correlated with increased metastases and poor prognosis in breast cancer[73,74,78]. The gene discussed is KRAS; the disease is neoplasm.